GeoVax Labs (GOVX) said late Monday Advanced Technology International notified the company to stop work on its phase 2b study to evaluate the GEO-CM04S1 COVID-19 vaccine.
Advanced Technology is the Rapid Response Partnership Vehicle's consortium management firm funded by the Biomedical Advanced Research and Development Authority of the US Department of Health and Human Services, according to its regulatory filing.
The notice indicated that BARDA decided to terminate the contract for convenience to the government, the filing said.
Shares of the company were down over 21% in Tuesday trading.
Price: 0.84, Change: -0.23, Percent Change: -21.50
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.